$13.59 Million in Sales Expected for MannKind Co. (MNKD) This Quarter

Equities research analysts expect MannKind Co. (NASDAQ:MNKD) to report sales of $13.59 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for MannKind’s earnings, with the highest sales estimate coming in at $16.00 million and the lowest estimate coming in at $10.14 million. MannKind reported sales of $3.89 million during the same quarter last year, which would suggest a positive year over year growth rate of 249.4%. The business is expected to issue its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that MannKind will report full-year sales of $74.53 million for the current fiscal year, with estimates ranging from $64.85 million to $92.70 million. For the next fiscal year, analysts anticipate that the firm will report sales of $99.51 million, with estimates ranging from $84.18 million to $114.26 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow MannKind.

MannKind (NASDAQ:MNKD) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02. The company had revenue of $17.45 million during the quarter, compared to analyst estimates of $18.03 million. During the same period in the previous year, the company earned ($0.25) EPS.

A number of research analysts have commented on MNKD shares. Svb Leerink started coverage on shares of MannKind in a research report on Friday, February 22nd. They issued an “outperform” rating and a $3.00 target price on the stock. Leerink Swann started coverage on shares of MannKind in a research note on Friday, February 22nd. They set an “outperform” rating and a $3.00 price target on the stock. BidaskClub upgraded shares of MannKind from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. HC Wainwright cut their price target on shares of MannKind from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, ValuEngine lowered shares of MannKind from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $2.85.

A number of large investors have recently modified their holdings of MNKD. CVI Holdings LLC purchased a new stake in MannKind during the fourth quarter worth about $11,359,000. Raging Capital Management LLC increased its stake in MannKind by 7,166.3% during the fourth quarter. Raging Capital Management LLC now owns 3,444,971 shares of the biopharmaceutical company’s stock worth $3,652,000 after purchasing an additional 3,397,561 shares during the period. Highbridge Capital Management LLC purchased a new stake in MannKind during the fourth quarter worth about $2,649,000. BlackRock Inc. increased its stake in MannKind by 12.7% during the third quarter. BlackRock Inc. now owns 11,682,722 shares of the biopharmaceutical company’s stock worth $21,381,000 after purchasing an additional 1,321,050 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of MannKind by 29.2% during the first quarter. Geode Capital Management LLC now owns 2,152,020 shares of the biopharmaceutical company’s stock worth $4,239,000 after buying an additional 485,916 shares during the period. Institutional investors own 30.26% of the company’s stock.

NASDAQ MNKD traded down $0.01 during trading hours on Friday, reaching $1.31. The company had a trading volume of 49,081 shares, compared to its average volume of 1,787,283. MannKind has a 1-year low of $0.94 and a 1-year high of $3.04. The stock has a market capitalization of $247.87 million, a P/E ratio of -2.22 and a beta of 2.56.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

Featured Story: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on MannKind (MNKD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.